SOURCE: ZELTIQ Aesthetics, Inc.

ZELTIQ Aesthetics, Inc.

April 26, 2016 09:00 ET

Hospira President, David J. Endicott, Joins ZELTIQ Aesthetics Board of Directors

Dr. Bryan Roberts Notifies Board He Won't Be Standing for Reelection

PLEASANTON, CA--(Marketwired - April 26, 2016) - ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced David J. Endicott has joined its Board of Directors.

"We are very pleased that David has agreed to join our Board of Directors. His broad operating experience combined with his extensive aesthetic background make him uniquely qualified to assist us as we look to grow and scale our business. David is well-known in the aesthetics community and has an appreciation for how to build a great franchise in this market," said Mark Foley, President and Chief Executive Officer of ZELTIQ. "We are excited to welcome David to ZELTIQ and believe that he will be a valuable addition to the Board of Directors."

"I am very excited to be joining ZELTIQ's Board of Directors," said David Endicott. "I have admired the Company's success from afar and believe that they are well-positioned to leverage their leadership role into a sustainable and leading franchise in the aesthetic field. I am particularly encouraged by ZELTIQ's demonstrated ability to expand the aesthetic market through body aesthetics and believe that this market has the ability for significant expansion over time."

Mr. Endicott served as President, Hospira Medical Devices, the world's leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, from March 2014 until September 2015 when Hospira was acquired by Pfizer Inc. Prior to joining Hospira, Mr. Endicott served as President, Allergan Medical, Asia Pacific and Latin America and as an executive committee member of Allergan, Inc., a global specialty drug and medical device company. Mr. Endicott currently serves on the board of directors of Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity and as a member of the board of directors for AdvaMed, the principal industry association for medical devices. He earned his bachelor's degree in chemistry from Whitman College, his master's in business administration from the University of Southern California and is a graduate of the Harvard Business School Advanced Management Program.

Concurrent with Mr. Endicott's appointment to the ZELTIQ Board of Directors, Dr. Bryan Roberts advised the company that he will not be standing for reelection to the Board of Directors at the upcoming annual meeting. "Bryan has provided us with invaluable insights and support over the years, particularly during challenging times, and we are very grateful to him for his longstanding commitment, service to ZELTIQ and significant contributions to our success," said Mr. Foley. "As the organization evolved, Bryan was gracious enough to extend his board commitment to ensure a successful and smooth transition. Personally, Bryan has been a great resource for me and I will miss our regular interactions."

About the CoolSculpting ® Procedure

The CoolSculpting procedure is a non-surgical, clinically proven procedure with high reliability and predictability that selectively reduces unwanted fat using a patented cooling technology. The CoolSculpting procedure is cleared by the FDA to treat visible fat bulges in the submental area, thigh, abdomen, flank, bra fat, back fat and infragluteal fold, also known as the banana roll. The CoolSculpting procedure works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. Millions of CoolSculpting treatments have been performed by nearly 4,000 CoolSculpting systems in over 70 countries. Market research indicates up to a 95 percent customer satisfaction rate with the CoolSculpting procedure. The CoolSculpting procedure is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at

Be sure to follow CoolSculpting on Facebook, Twitter, Pinterest and YouTube.

About ZELTIQ ® Aesthetics, Inc.

ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting system, is designed to selectively reduce unwanted fat that may not respond to diet or exercise. The CoolSculpting procedure is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed the CoolSculpting procedure to safely, noticeably, and measurably reduce the fat layer.